{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T10:28:56Z","timestamp":1791628136674,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.clbc.2017.10.003","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T12:34:14Z","timestamp":1507811654000},"page":"e501-e506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes"],"prefix":"10.1016","volume":"18","author":[{"given":"Tina J.","family":"Hieken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany L.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy C.","family":"Boughey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy C.","family":"Degnim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina N.","family":"Glazebrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya L.","family":"Hoskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2017.10.003_bib1","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1200\/JCO.2015.65.2289","article-title":"Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline","volume":"34","author":"Harris","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2017.10.003_bib2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000430488","article-title":"St Gallen\/Vienna 2015: a brief summary of the consensus discussion","volume":"10","author":"Gnant","year":"2015","journal-title":"Breast Care"},{"key":"10.1016\/j.clbc.2017.10.003_bib3","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2017.10.003_bib4","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/cncr.27995","article-title":"Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017","volume":"119","author":"De Los Santos","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2017.10.003_bib5","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/SLA.0000000000000924","article-title":"Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial","volume":"260","author":"Boughey","year":"2014","journal-title":"Ann Surg"},{"key":"10.1016\/j.clbc.2017.10.003_bib6","series-title":"AJCC Cancer Staging Manual","year":"2010"},{"key":"10.1016\/j.clbc.2017.10.003_bib7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/annonc\/mdq345","article-title":"International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment","volume":"22","author":"Dawood","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2017.10.003_bib8","series-title":"WHO Classification of Tumours of the Breast","year":"2012"},{"key":"10.1016\/j.clbc.2017.10.003_bib9","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/(SICI)1097-0142(19980615)82:12<2366::AID-CNCR10>3.0.CO;2-N","article-title":"Inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results program of the National Cancer Institute, 1975-1992","volume":"82","author":"Chang","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2017.10.003_bib10","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1200\/JCO.2003.07.082","article-title":"Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities?","volume":"21","author":"Anderson","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2017.10.003_bib11","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/jnci\/dji172","article-title":"Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results program at the National Cancer Institute","volume":"97","author":"Hance","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2017.10.003_bib12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/01.cco.0000245307.29026.0a","article-title":"Inflammatory breast cancer: current understanding","volume":"18","author":"Dirix","year":"2006","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clbc.2017.10.003_bib13","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.surg.2016.06.030","article-title":"Contemporary operative management of T4 breast cancer","volume":"160","author":"Murphy","year":"2016","journal-title":"Surgery"},{"key":"10.1016\/j.clbc.2017.10.003_bib15","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/S0360-3016(02)04201-3","article-title":"Ten-year outcome after combined modality therapy for inflammatory breast cancer","volume":"55","author":"Harris","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clbc.2017.10.003_bib16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1001\/archsurg.141.6.567","article-title":"A\u00a0single-center experience with inflammatory breast cancer, 1985-2003","volume":"141","author":"Smoot","year":"2006","journal-title":"Arch Surg"},{"key":"10.1016\/j.clbc.2017.10.003_bib17","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1002\/cncr.22927","article-title":"Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease","volume":"110","author":"Cristofanilli","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2017.10.003_bib18","first-page":"351","article-title":"Inflammatory breast cancer: the disease, the biology, the treatment","volume":"60","author":"Robertson","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clbc.2017.10.003_bib19","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1634\/theoncologist.2012-0039","article-title":"Inflammatory breast cancer: what we know and what we need to learn","volume":"17","author":"Yamauchi","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2017.10.003_bib20","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ijrobp.2012.01.030","article-title":"Modern outcomes of inflammatory breast cancer","volume":"84","author":"Rehman","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clbc.2017.10.003_bib21","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1200\/JCO.2014.55.1978","article-title":"Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database","volume":"32","author":"Rueth","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2017.10.003_bib22","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/annonc\/mdu121","article-title":"Survival of women with inflammatory breast cancer: a large population-based study","volume":"25","author":"Dawood","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2017.10.003_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clbc.2014.05.005","article-title":"Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome","volume":"15","author":"Matro","year":"2015","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2017.10.003_bib24","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clbc.2016.02.004","article-title":"Inflammatory TNBC breast cancer: demography and clinical outcome in a large cohort of patients with TNBC","volume":"16","author":"Biswas","year":"2016","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2017.10.003_bib25","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2017.10.003_bib26","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2017.10.003_bib27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2017.10.003_bib28","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/annonc\/mdt525","article-title":"Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor\u2013 and HER2-defined subtypes","volume":"25","author":"Masuda","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2017.10.003_bib29","doi-asserted-by":"crossref","first-page":"58162","DOI":"10.18632\/oncotarget.11262","article-title":"Matriptase regulates c-Met mediated proliferation and invasion in inflammatory breast cancer","volume":"7","author":"Zoratti","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clbc.2017.10.003_bib30","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2004.04.068","article-title":"Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy","volume":"22","author":"Low","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2017.10.003_bib31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00432-016-2281-6","article-title":"Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database","volume":"143","author":"Liu","year":"2017","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clbc.2017.10.003_bib32","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.2003.02.063","article-title":"Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer","volume":"21","author":"Henderson","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2017.10.003_bib33","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3816\/CBC.2004.n.004","article-title":"Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the MD Anderson Cancer Center experience","volume":"4","author":"Cristofanilli","year":"2004","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2017.10.003_bib34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2967\/jnumed.112.106864","article-title":"18F-FDG PET\/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging","volume":"54","author":"Groheux","year":"2013","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.clbc.2017.10.003_bib35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clbc.2013.04.002","article-title":"Risk factors for locoregional failure in patients with inflammatory breast cancer treated with trimodality therapy","volume":"13","author":"Saigal","year":"2013","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2017.10.003_bib36","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S1470-2045(16)00011-5","article-title":"Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study","volume":"17","author":"Bertucci","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2017.10.003_bib37","first-page":"2077","article-title":"Prognostic impact of hormone receptor\u2013 and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study","volume":"7","author":"Boudin","year":"2016","journal-title":"J\u00a0Cancer"},{"key":"10.1016\/j.clbc.2017.10.003_bib38","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/COC.0b013e3182937921","article-title":"Outcomes after multidisciplinary treatment of inflammatory breast cancer in the era of neoadjuvant HER2-directed therapy","volume":"38","author":"Tsai","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clbc.2017.10.003_bib39","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1470-2045(14)70080-4","article-title":"Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort","volume":"15","author":"Gianni","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2017.10.003_bib40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/annonc\/mdw535","article-title":"Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab","volume":"28","author":"Pierga","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820917303701?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820917303701?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:18:04Z","timestamp":1761513484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820917303701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1526820917303701"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2017.10.003","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2017.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}